Is NSCLC up or down today?
NSCLC is up 0.08% today, last at 59.73. This stock moved +0.08% versus the prior close.
NSCLC · NSCLC
NSCLC (NSCLC) is trading at 59.73, up 0.08% on the session. NSCLC sits at the 50% mark of its 52-week range.
Leading the coverage: “Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB) - Seeking Alpha” (Google News Company, 12d ago). NSCLC is -6.48% since story.
NSCLC trades on a trailing P/E of 15.7.
Analyst firms are mostly reiterating — no strong directional shift lately.
NSCLC is up 0.08% today, last at 59.73. This stock moved +0.08% versus the prior close.
Leading the coverage: “Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB) - Seeking Alpha” (Google News Company, 12d ago). NSCLC is -6.48% since story. Dominant story: SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China - Yahoo Finance (1 source, bullish) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China - Yahoo Finance
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB) - Seeking Alpha
Basement Membrane Remodeling Fuels NSCLC Invasion, Treatment Resistance - The American Journal of Managed Care
AbbVie's ABBV-1480 Posts 90% Response Rate in Frontline NSCLC Combination - BioPharm International
Review Maps 15 Years of Targeted Therapy Growth in Fusion-Driven NSCLC - The American Journal of Managed Care